-transparent.png){kind=logo}
Dose proportionality of racemic bisoprolol and the stereoselectivity of its enantiomers were studied after single oral dosing of 5 to 40 mg of bisoprolol hemifumarate in eight healthy male volunteers in an open-label, randomized, four-way cross-over trial. There were dose-proportional increases in mean peak plasma concentration (Cmax) and area under the plasma concentration versus time curve (AUC) values for the racemate and the individual enantiomers. No statistically significant differences were detected between the mean half life (t 1/2), Cmax, and time to reach Cmax (tmax) of the R- and S-isomers at each of the four dose levels studied. These findings support dose proportionality and absence of stereoselective pharmacokinetics for bisoprolol in the dose range studied.
A Dutta, and
R Lanc, and
E Begg, and
R Robson, and
L Sia, and
G Dukart, and
R Desjardins, and
A Yacobi
July 2001,
Clinical pharmacology and therapeutics,
A Dutta, and
R Lanc, and
E Begg, and
R Robson, and
L Sia, and
G Dukart, and
R Desjardins, and
A Yacobi
September 1984,
The Journal of clinical psychiatry,
A Dutta, and
R Lanc, and
E Begg, and
R Robson, and
L Sia, and
G Dukart, and
R Desjardins, and
A Yacobi
February 1986,
Antimicrobial agents and chemotherapy,
A Dutta, and
R Lanc, and
E Begg, and
R Robson, and
L Sia, and
G Dukart, and
R Desjardins, and
A Yacobi
April 2006,
Biopharmaceutics & drug disposition,
A Dutta, and
R Lanc, and
E Begg, and
R Robson, and
L Sia, and
G Dukart, and
R Desjardins, and
A Yacobi
February 2016,
Journal of veterinary pharmacology and therapeutics,
A Dutta, and
R Lanc, and
E Begg, and
R Robson, and
L Sia, and
G Dukart, and
R Desjardins, and
A Yacobi
June 1987,
The Journal of pharmacology and experimental therapeutics,
A Dutta, and
R Lanc, and
E Begg, and
R Robson, and
L Sia, and
G Dukart, and
R Desjardins, and
A Yacobi
December 1992,
Biopharmaceutics & drug disposition,
A Dutta, and
R Lanc, and
E Begg, and
R Robson, and
L Sia, and
G Dukart, and
R Desjardins, and
A Yacobi
March 1998,
Journal of pharmaceutical sciences,
A Dutta, and
R Lanc, and
E Begg, and
R Robson, and
L Sia, and
G Dukart, and
R Desjardins, and
A Yacobi
January 1989,
Biopharmaceutics & drug disposition,
A Dutta, and
R Lanc, and
E Begg, and
R Robson, and
L Sia, and
G Dukart, and
R Desjardins, and
A Yacobi
November 1986,
Clinical pharmacology and therapeutics,
